- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06006559
Een onderzoek om de werkzaamheid, veiligheid en farmacokinetiek van EYU688 bij patiënten met dengue-koorts te beoordelen
Een gerandomiseerde, door deelnemers en onderzoekers geblindeerde, placebogecontroleerde, parallelle groepsstudie om de werkzaamheid, veiligheid en farmacokinetiek van EYU688 bij patiënten met dengue-koorts te beoordelen
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a randomized, participant- and investigator- blinded, placebo-controlled study to investigate the efficacy and safety of EYU688 administered orally in patients with dengue fever.
Due to the different PK sampling schedules applied, the study consists of two cohorts run in parallel (intensive PK [cohort 1] and sparse PK sampling [cohort 2]).
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Novartis Pharmaceuticals
- Telefoonnummer: +41613241111
- E-mail: novartis.email@novartis.com
Studie Contact Back-up
- Naam: Novartis Pharmaceuticals
Studie Locaties
-
-
Amazonas
-
Manaus, Amazonas, Brazilië, 69040-000
- Werving
- Novartis Investigative Site
-
-
Federal District
-
Brasília, Federal District, Brazilië, 71635-580
- Werving
- Novartis Investigative Site
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazilië, 90560-032
- Werving
- Novartis Investigative Site
-
-
Rio de Janeiro
-
Rio de Janeiro, Rio de Janeiro, Brazilië, 21040-360
- Werving
- Novartis Investigative Site
-
-
São Paulo
-
Sorocaba, São Paulo, Brazilië, 18040-425
- Werving
- Novartis Investigative Site
-
São Caetano do Sul, São Paulo, Brazilië, 09521-160
- Werving
- Novartis Investigative Site
-
São José do Rio Preto, São Paulo, Brazilië, 15090 000
- Werving
- Novartis Investigative Site
-
-
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080012
- Werving
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombia, 681017
- Werving
- Novartis Investigative Site
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760032
- Werving
- Novartis Investigative Site
-
-
-
-
Karnataka
-
Belagavi, Karnataka, Indië, 590010
- Werving
- Novartis Investigative Site
-
-
Maharashtra
-
Mumbai, Maharashtra, Indië, 400008
- Ingetrokken
- Novartis Investigative Site
-
Pune, Maharashtra, Indië, 411013
- Werving
- Novartis Investigative Site
-
-
Rajasthan
-
Jaipur, Rajasthan, Indië, 302017
- Werving
- Novartis Investigative Site
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Indië, 600113
- Werving
- Novartis Investigative Site
-
-
-
-
-
Kuala Selangor, Maleisië, 68000
- Werving
- Novartis Investigative Site
-
-
Pahang
-
Kuantan, Pahang, Maleisië, 25200
- Werving
- Novartis Investigative Site
-
-
Perak
-
Ipoh, Perak, Maleisië, 30450
- Werving
- Novartis Investigative Site
-
-
Pulau Pinang
-
Seberang Jaya, Pulau Pinang, Maleisië, 13700
- Werving
- Novartis Investigative Site
-
-
Sarawak
-
Miri, Sarawak, Maleisië, 98000
- Werving
- Novartis Investigative Site
-
-
-
-
-
Oaxaca City, Mexico, 68020
- Werving
- Novartis Investigative Site
-
Veracruz, Mexico, 91855
- Werving
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapore, 169608
- Werving
- Novartis Investigative Site
-
-
Singapore
-
Singapore, Singapore, Singapore, 308433
- Werving
- Novartis Investigative Site
-
-
-
-
-
Haiphong, Vietnam, 180000
- Werving
- Novartis Investigative Site
-
Hanoi, Vietnam, 100000
- Werving
- Novartis Investigative Site
-
Ho Chi Minh City, Vietnam, 700000
- Werving
- Novartis Investigative Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Male or female, 18 - 60 years old (inclusive).
- History or presence of fever (≥ 38°C). At least one of the following criteria indicating dengue infection:
- Nausea or vomiting.
- Presence of rash, aches or pains including headache, muscle or joint pain.
- Onset of fever ≤ 48 hours prior to treatment start.
- Positive test on dengue fever.
Exclusion Criteria:
-
Participants with any of abnormalities of clinical laboratory parameters.
-
Usage of any anticoagulant drugs.
-
Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug.
-
Pregnant or nursing (lactating) women.
-
Clinical signs and symptoms for severe dengue according to Dengue Guideline (WHO 2009) at screening.
-
Participants with any of the following abnormalities of clinical laboratory parameters at screening:
- Hemoglobin <12.0 g/dL in males; <11.0 g/dL in females
- Hematocrit >52 % in males; >46 % in females
- Absolute neutrophil count <1500/μL
- Platelet count <80,000/mm3
- Creatinine >165 μmol/L in males; >130 μmol/L in females
- Serum creatine kinase > 600 U/L
- ALT, AST levels more than 3 X upper limit of normal (ULN)
- Total bilirubin >24 μmol/L
-
Usage of PPIs (proton pump inhibitor) which could affect absorption of EYU688 due to stomach pH value increase up to 48 hours prior to screening.
-
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug.
-
History or long-QT syndrome, or clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening:
- QTcF > 450 msec (males)
- QTcF > 460 msec (females)
Other protocol-defined inclusion/exclusion criteria may apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo
Matching placebo |
Matching placebo administered orally as capsules |
|
Experimenteel: EYU688
EYU688 administered by oral route |
EYU688 administered by oral route |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Viremia reduction (viral load reduction (VLR) on log scale) at 48 hours post treatment start
Tijdsspanne: From predose to 48 hours post treatment start
|
Efficacy assessment of EYU688. It will allow to quantify the viremia reduction at 48 hours post treatment start from baseline. |
From predose to 48 hours post treatment start
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time from fever onset to start of the first 48 hours period during which the oral temperature remained below 37.5℃
Tijdsspanne: From fever onset to Day 15
|
Efficacy assessment of EYU688. It will allow to assess the time needed between fever onset and defervescence. |
From fever onset to Day 15
|
|
Time from fever onset to the first of two consecutive negative viremia by PCR
Tijdsspanne: From fever onset to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day15 |
From fever onset to Day 15
|
|
Area under the log-transformed viremia curve (AUC) from the first dose to Day 15
Tijdsspanne: From fever onset to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day 15 |
From fever onset to Day 15
|
|
Changes of viral load over time
Tijdsspanne: From baseline to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day15 |
From baseline to Day 15
|
|
Incidence and severity of Adverse Events (AEs)
Tijdsspanne: From inclusion to Day 15
|
Incidence and severity of AEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs. |
From inclusion to Day 15
|
|
Incidence and severity of Serious Adverse Events (SAEs)
Tijdsspanne: From inclusion to Day 35
|
Incidence and severity of SAEs by treatment group |
From inclusion to Day 35
|
|
Change of white blood cell count over time from baseline
Tijdsspanne: From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of platelet count over time
Tijdsspanne: From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of hematocrit level and percentage increase from baseline over time
Tijdsspanne: From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of AST, ALT levels over time
Tijdsspanne: From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
No warning signs by day 7 of fever onset
Tijdsspanne: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Diagnosis of severe dengue fever
Tijdsspanne: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Diagnosis of dengue hemorrhagic fever (DHF)
Tijdsspanne: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Plasma leakage
Tijdsspanne: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Requiring fluid infusion
Tijdsspanne: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Time from fever onset to clinical recovery
Tijdsspanne: From fever onset to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From fever onset to Day 15
|
|
PK parameter (Cmax)
Tijdsspanne: From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK parameter (Tmax)
Tijdsspanne: From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK parameter (partial AUCs)
Tijdsspanne: From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK concentrations following multiple doses
Tijdsspanne: From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CEYU688A12201
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .